Abatacept

被引：140

作者：

Moreland, L

Bate, G

Kirkpatrick, P

机构：

[1] Univ Alabama, Dept Med, Birmingham, AL 35294 USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 03期

关键词：

D O I：

10.1038/nrd1989

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In December 2005, abatacept (Orencia; Bristol-Myers Squibb), a fusion protein that selectively modulates a costimulatory signal necessary for T-cell activation, was approved by the US FDA for the treatment of patients with rheumatoid arthritis who have had an inadequate response to other drugs. It is the first selective costimulation modulator to be approved.

引用

页码：185 / 186

页数：2

共 12 条

[1] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld, FC
Weisman, MH
Kavanaugh, AF
Cohen, SB
Pavelka, K
van Vollenhoven, R
Sharp, J
Perez, JL
Spencer-Green, GT
[J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (01): : 26 - 37
[2] *FDA, 2005, FDA LAB INF
[3] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
Genovese, MC
Becker, J
Schiff, M
Luggen, M
Sherrer, Y
Kremer, J
Birbara, C
Box, J
Natarajan, K
Nuamah, I
Li, T
Aranda, R
Hagerty, DT
Dougados, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) : 1114 - 1123
[4] Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Klareskog, L
van der Heijde, D
de Jager, JP
Gough, A
Kalden, J
Malaise, M
Mola, EM
Pavelka, K
Sany, J
Settas, L
Wajdula, J
Pedersen, R
Fatenejad, S
Sanda, M
[J]. LANCET, 2004, 363 (9410) : 675 - 681
[5] Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
Kremer, JM
Westhovens, R
Leon, M
Di Giorgio, E
Alten, R
Steinfeld, S
Russell, A
Dougados, M
Emery, P
Nuamah, IF
Williams, GR
Becker, JC
Hagerty, DT
Moreland, LW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) : 1907 - 1915
[6] CTLA-4 IS A 2ND RECEPTOR FOR THE B-CELL ACTIVATION ANTIGEN-B7
LINSLEY, PS
BRADY, W
URNES, M
GROSMAIRE, LS
DAMLE, NK
LEDBETTER, JA
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (03) : 561 - 569
[7] IMMUNOSUPPRESSION INVIVO BY A SOLUBLE FORM OF THE CTLA-4 T-CELL ACTIVATION MOLECULE
LINSLEY, PS
WALLACE, PM
JOHNSON, J
GIBSON, MG
GREENE, JL
LEDBETTER, JA
SINGH, C
TEPPER, MA
[J]. SCIENCE, 1992, 257 (5071) : 792 - 795
[8] Infliximab and methotrexate in the treatment of rheumatoid arthritis
Lipsky, PE
van der Heijde, DMFM
St Clair, EW
Furst, DE
Breedveld, FC
Kalden, JR
Smolen, JS
Weisman, M
Emery, P
Feldmann, M
Harriman, GR
Maini, RN
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
[9] Costimulatory blockade in patients with rheumatoid arthritis a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
Moreland, LW
Alten, R
Van den Bosch, F
Appelboom, T
Leon, M
Emery, P
Cohen, S
Luggen, M
Shergy, W
Nuamah, I
Becker, JC
[J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (06): : 1470 - 1479
[10] Mechanisms of disease - Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
Reiser, H
Stadecker, MJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) : 1369 - 1377

← 1 2 →